Table 3.
Clinical Characteristics as a Function of Serum Hepatoma-derived Growth Factor
| HDGFlow (n = 32) | HDGFhigh (n = 41) | P Value | |
|---|---|---|---|
| Demographics | |||
| Age, yr, median (range) | 58 (50–62) | 56 (52–72) | 0.06 |
| Female sex, n (%) | 25 (78%) | 34 (83%) | 0.80 |
| Race, n (%) | 0.70 | ||
| EA | 26 (81%) | 36 (85%) | |
| AA | 6 (19%) | 5 (12%) | |
| Other | 0 (0%) | 0 (0%) | |
| IPAH, n (%) | 20 (69%) | 21 (49%) | 0.08 |
| APAH, n (%) | 12 (31%) | 21 (51%) | |
| 6MWD, m, median (range) | 410 (369–475) | 357 (300–415) | 0.04 |
| NYHA-FC, n | |||
| I/II | 23 | 17 | 0.02 |
| III/IV | 9 | 24 | |
| Laboratory chemistry, median (range) | |||
| NTproBNP, pg/ml | 341 (136–1,794) | 894 (410–3,378) | 0.03 |
| Sodium, mEq/L | 140 (137–141) | 139 (138–140) | 0.37 |
| Creatinine, mg/dl | 1.0 (0.8–1.1) | 1 (0.8–1.3) | 0.15 |
| Hemodynamics, median (range) | |||
| RAP, mm Hg | 8 (6–13) | 6 (4–12) | 0.07 |
| mPAP, mm Hg | 44 (34–53) | 42 (29–50) | 0.22 |
| PVR, WU | 8.3 (6.6–12.3) | 7.3 (4.7–12.9) | 0.84 |
| CO, L/min | 4.6 (3.8–6.2) | 4.2 (3.5–5.2) | 0.07 |
| Cardiac index, L/min/m2 | 2.5 (2.2–3.2) | 2.3 (1.9–2.9) | 0.31 |
Definition of abbreviations: 6MWD = 6-minute-walk distance; AA = African American; APAH = associated pulmonary arterial hypertension; CO = cardiac output; EA = European American; HDGFhigh = hepatoma-derived growth factor level above 0.7 ng/ml cutoff; HDGFlow = hepatoma-derived growth factor level below 0.7 ng/ml cutoff; IPAH = idiopathic pulmonary arterial hypertension; mPAP = mean pulmonary arterial pressure; NTproBNP = N-terminal pro–brain natriuretic peptide; NYHA-FC = New York Heart Association functional class; PVR = pulmonary vascular resistance; RAP = right atrial pressure; WU = Wood units.
Data are expressed as median (range) or number (percent).